Taikong Corporation and Huai-Jen Tsai have been awarded US Patent 7,365,177, “Recombinant plasmid expressing two fluorescence genes.”
The inventor listed in the patent is Huai-Jen Tsai.
According to its abstract, the patent describes recombinant plasmids comprising (a) a ubiquitous promoter, (b) one fluorescent gene, the gene being operably liked to and inserted downstream of the ubiquitous promoter, (c) a skin-specific or muscle-specific promoter, and (d) another fluorescent gene, the gene being operably linked to and inserted downstream of the skin-specific or muscle specific promoter. The ubiquitous promoter and the skin-specific or muscle promoter have the adverse directional property and are located upstream of the fluorescent gene.
Multi-Gene Vascular Systems has been awarded US Patent 7,364,725, “Endothelial cells engineered to express or overexpress fibulin-5 and a growth factor.”
The inventor listed on the patent is Moshe Flugelman.
The invention relates to endothelial and smooth muscle cells genetically altered to express or over-express one or more cell adhesion factors, its abstract said. The patent also relates to cells that have been genetically altered to express or over-express both cell proliferation growth factor(s) and cell adhesion factor(s). In addition, the present invention relates to nucleic acid constructs and nucleic acid construct systems that encode the cell adhesion and cell proliferation growth factors, and that are used to transfect/transform the cells so that they express the factors.